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Bile acids modulate hepatocellular signaling pathways in vitro at physiological
concentrations. Thepresentpaperprovides abriefoverview oftheeffects ofbile
acids on three key messengers in liver cells: cytosolic free calcium, protein
kinase A and protein kinase C.
INTRODUCTION
Liver cell functions are modulated by a complex network of intracellular and trans-
membraneous signaling mechanisms. Notonly hormones, but also bile acids have increas-
ingly been recognized to triggerhepatocellular signaling mechanisms in vitro [1-12]. This
article is aimed to give a brief overview on the present knowledge of bile acid-mediated
modulation ofhepatocellular signaling. It will focus on three key messengers ofthe hepa-
tocellular signaling network: cytosolic free Cal [Ca++]i, protein kinase A (PKA), and
protein kinase C (PKC).
EFFECTS OF BILE ACIDS ON [Ca++]i
Cytosolic free calcium [Ca+]i is ofkey importance for the control ofmany cell func-
tions, including secretion [13, 14]. [Ca++]i levels in hepatocytes are 100-200 nM under
resting conditions. Increases in [Ca++]i are induced by depletion ofinositol 1,4,5-trispho-
sphate (IP3)-sensitive or ryanodine- and Ca++-sensitive microsomal stores as well as by
Ca" influx across the plasma membrane [13, 14]. [Ca++]i levels are renormalized by
active, ATP-dependent Ca++ extrusion mechanisms across the plasma membrane or the
membranes ofthe endoplasmic reticulum. [Ca++]i levels are ten-thousand-fold lower than
extracellular levels (10-3 M) and a thousand-fold lower than those within the endoplasmic
Ca++ stores (104 M).
It has been assumed previously that bile acid-induced hepatotoxicity and cholestasis
may also be mediated by changes in [Ca+]i [1, 3, 4]. Because hydrophilic taurine- and
glycine-conjugated ursodeoxycholic acid (TUDCA, GUDCA) protect hepatocytes from
more hydrophobic bile acids in vitro and in vivo [15-17], we studied the effect ofTUDCA
in comparison to other bile acids on [Ca++]i in groups ofisolated hepatocytes in short-term
culture using microspectrofluorometry [7, 8]. We observed that the hydrophilic bile acid
TUDCA, at a physiological concentration of only 5 ,uM, induced a sustained increase of
[Ca+]i of about 400 nM [7], reflecting the maximum sustained response of hepatocytes
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under physiological conditions [14]. The effect ofTUDCA at low micromolar concentra-
tions on [Ca+]i was stronger than that of any other bile acid tested at equimolar concen-
trations [7] and was due to IP3-independent depletion of IP3-sensitive endoplasmic Ca"
stores and to stimulation of influx of extracellular Ca' across the plasma membrane via
Ni++-sensitive Ca++ channels [7, 8, 10; Table 1]. In contrast to TUDCA, the primary bile
acid TCA did not affect [Ca+]i at low and high micromolar levels [1, 3, 7; Table 1]. The
hydrophobic bile acid TLCA also induced an increase of [Ca++]j, but this [Ca"]i increase
was only transient [1, 5, 7; Table 1]. This may be due to lack ofCa++ influx [5] and/or due
to activation ofCa++ extrusion mechanisms [2]. IP3 formation was not affected by any of
these bile acids [4, 7, 10] indicating that phosphoinositolbisphospate-dependent phospho-
lipase C is not a target ofbile acids (Table 1).
Table 1: Effects ofbile acids on hepatoceilular Ca++ homeostasis.
TUDCA TCA TLCA
[Ca++i] + - +
Ca-+ influx + -
Ca++ extrusion - - +
Depletion ofIP3- + - +
sensitive Ca++ stores
IP3 formation
From Refs.1-5, 7, 8, 10; * controversial data; see text for details.
A sustained [Ca"]i increase is the key signal for the stimulation of regulated exocy-
tosis in a number of secretory cells, including pancreatic acinar cells, platelets, and chro-
maffine cells [18]. In the liver cell, stimulation of exocytosis may lead to targeting and
insertion of tranport proteins in the canalicular membrane, thereby regulating bile excre-
tory function [19, 20]. In experimental cholestasis, the process ofhepatocellular exocyto-
sis is impaired [21, 22].
The effect of bile acids on hepatocellular exocytosis was studied in the isolated per-
fused rat liver. In livers preloaded with horseradish peroxidase (HRP), an established
marker of the vesicular pathway, TUDCA, but neither TCA nor TCDCA induced a sus-
tained stimulation of biliary HRP secretion [8]. This effect was Call-dependent and was
not observed when extracellular Cal+ was lowered to levels below 0.2 mM, low enough
to prevent an agonist-induced sustained increase of[Ca++]i, yet adequate to prevent Ca++-
deprivation-induced cholestasis in the perfused rat liver [8]. Thus, TUDCA stimulates
hepatocellular exocytosis by Ca++-dependent mechanisms.
EFFECTS OF BILE ACIDS ON PROTEIN KINASE A
Cyclic AMP is the physiological activator of protein kinase A (PKA) and is formed
from ATP by adenylate cyclase. Cyclic AMP is implicated in numerous hepatocellular
processes including bile secretion [13]. The effect of dihydroxy bile acids on cAMP for-
mation has been studied in isolated hamster hepatocytes [11]. UDCA and CDCA did not
affect basal levels of cAMP although UDCA impaired glucagon-induced increases of
cAMP in aprotein kinase C-dependent way [ 1]. Thus, dihydroxy bile acids do not direct-
ly affect PKA activity in hepatocytes.
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EFFECTS OF BILE ACIDS ON PROTEIN KINASE C
The protein kinase C (PKC) family of isoenzymes regulates numerous functions of
the liver cell including bile formation [13, 23-25]. At least 10 different PKC isoforms have
been identified in man [26, 27], and five of them (a, [ II, 6, £, 4) have been described in
liver cells [9, 12]. Activation ofPKC isoforms involves 2 major steps [26, 27]: (i) translo-
cation of the protein from cytosol to the membranes with binding to membrane phos-
phatidylserine residues, translocation ofthe conventional isoforms a, 1B, and ybeing Ca++-
dependent; (ii) binding of the physiological activator sn-1,2-diacylglycerol (DAG) to the
regulatory site of the PKC molecule leading to (iii) activation of the membrane-bound
enzyme.
(i) Translocation ofPKC isoforms by bile acids
TUDCA at low 10 iM concentrations induced translocation of the Ca++-sensitive a-
isoform from cytosol to the membranes as observed by Western blotting studies and con-
firmed by immunohistochemistry [9]. However, the 6-, £-, and 4-isoform were not affect-
ed by TUDCA in isolated hepatocytes in short-term culture [9]. Translocation of a-PKC
by TUDCA was also observed inprimary hepatocyte cultures by Stravitz et al. [12] as well
as in isolated hamster hepatocytes by Bouscarel et al. [11]. Thus, TUDCA apparently
induces translocation of only the Ca++-sensitive a-isoform in hepatocytes at low micro-
molar concentrations (Table 2).
Table 2: Effect ofbile acids on hepatocellular protein kinase C
TUDCA TCA TLCA
Translocation to membranes of:





DAG formation + + +
Activation of + + +
membrane-bound total PKC
Compiled from Refs. 9,11,12; * controversial data; ** Beuers et al., Hepatology 26:262A, 1997; see
text for details.
In contrast, immunoblotting and immunohistochemical studies did not reveal an
effect ofTCA at low 10 jM concentrations on the distribution ofPKC isoforms in isolat-
ed hepatocytes in short-term culture [9] whereas TCA at higher concentrations caused
translocation ofthe a, 6, and E isoforms in primary hepatocytes cultured for at least 18 hr
[12; Table 2]. These differences may depend on the differences in the experimental con-
ditions (e.g., metabolically active vs. resting state depending on the period ofculture; hor-
mones added to the culture medium; rate ofbile acid uptake; bile acid concentrations cho-
sen). Preliminary data indicate that the hydrophobic bile acid taurolithocholic acid
(TLCA) induces translocation of only the E-isoform at low micromolar concentrations in
freshly isolated rat hepatocytes (Beuers et al., Hepatology 26:262A, 1997; Table 2).
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(ii) Accumulation ofsn-1,2-diacylglycerol (DAG)
The formation of sn-1,2-diacylglycerol (DAG) and the binding of DAG to the DAG
binding site in the C1 region ofthe PKC molecule is required for activation ofthe enzyme
[26, 27]. DAG formation is mainly mediated by phospholipase C and phospholipase D
isoforms in mammalian cells [28]. Phospholipase C isoforms tend to induce a transient
increase of DAG mass with a maximum after 1-2 min, whereas a sustained increase of
DAG mass in mammalian cells may mainly result from cleavage of phosphatidylcholine
by the sequential action ofphospholipase D and phosphatidic acid hydrolase [28, 29].
A number ofbile acids, including TUDCA, TCA, TCDCA, and TLCA, induce a sus-
tained accumulation of DAG mass in isolated hepatocytes in short-term culture as deter-
mined by a combinedradioenzymatic andchromatographic technique [9] (Table 2). These
findings together with the observation that TUDCA and other bile acids do not affect IP3
levels in hepatocytes [see above; 4, 7, 10], suggest that bile acid-induced DAG accumula-
tion is mainly caused by cleavage of phosphatidylcholine as mediated by the sequential
activation ofphospholipase D and phosphatidic acid hydrolase [9].
(iii) Activation ofmembrane-bound PKC
Activation of total membrane-bound PKC (all isoforms) by bile acids was expected
since a prerequisite for activation by bile acids, i.e., stimulation of hepatocellular DAG
accumulation has been demonstrated. However, the pattern ofmembrane-bound PKC iso-
forms depends on the bile acid to which the cell is exposed. Indeed, TUDCA as well as
TCA induced a sustained activation of total membrane-associated PKC in isolated hepa-
tocytes in short-term culture [9] in line with their effect on DAG accumulation in isolated
hepatocytes (Table 2). The stimulating effect of bile acids on hepatocellular PKC activity
was confirmed by studies performed in vitro [30]. In those studies, activation ofPKC was
related to the degree ofhydrophobicity of a bile acid [30], a phenomenon which was not
observed in hepatocytes in short-term culture [9]. The reason for these differences remains
unclear, although the sinusoidal uptake rates of bile acids may differ under different cul-
ture conditions.
MODEL OF TUDCA-INDUCED STIMULATION OF
HEPATOCELLULAR SECRETION
UDCA improves biochemical and histological parameters [31] and prolongs survival
in patients with primary biliary cirrhosis [32, 33]. Similar effects of UDCA on biochemi-
cal (and partly histological) parameters have been described in other chronic cholestatic
diseases, such as primary sclerosing cholangitis [34-36], cystic fibrosis-associated liver
disease [37], and progressive familial intrahepatic cholestasis [38]. However, the effect of
UDCA on survival time has not been established, due to the limited number of patients
who have participated in controlled trials. The mechanism of action of UDCA is still
unclear although experimental evidence suggests that stimulation ofhepatocellular secre-
tion by UDCA conjugates may be ofkey importance for the beneficial effect ofUDCA in
cholestatic disorders [15, 39].
The differential effects ofbile acids on signaling and secretory mechanisms ofthe liver
cell led us to propose a model ofTUDCA-induced stimulation ofhepatocellular secretion
[7-9]: After carrier-mediated uptake into the hepatocyte, TUDCA induces a sustained
increase of[Ca++]i by depleting IP3-sensitive microsomal Ca++-stores independently ofIP3
and by stimulating Call influx across the plasmamembrane viaNil'-sensitive Ca++-chan-
nels. The Ca++ increase may induce translocation of the Ca++-sensitive a-isoform of PKC
to the membranes as seen in other cell systems. Bile acid-induced accumulation of DAG
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may then activate the membrane-associated a-PKC. TUDCA stimulates sustained, Ca++-
dependent vesicular exocytosis which may also be mediated by a-PKC. We speculate that
TUDCA may enhance the secretory capacity of the cholestatic liver cell as it does in nor-
mal liver by stimulating apical exocytosis and thereby inducing targeting and insertion of
transport proteins into the canalicular membrane [8, 9, 40].
SUMMARY
Two of the key messengers ofthe hepatocellular signaling network, [Ca++]i and pro-
tein kinase C (but not cAMP-dependent protein kinase A), are directly modulated by bile
acids at physiological concentrations in isolated liver cells. The functional implications of
bile acid-induced signaling in liver cells are still incompletely understood.
REFERENCES
1. Anwer, M.S., Engelking, L.R., Sullivan, D., Zimniak, P., and Lester, R. Hepatotoxic bile acids
increase cytosolic Ca++ activity of isolated rat hepatocytes. Hepatol. 8:887-891, 1988.
2. Anwer, M.S., Little, J.M., Oelberg, D.G., Zimniak, P., and Lester, R. Effect ofbile acids on Ca++
efflux from isolated rat hepatocytes and perfused rat livers. Proc. Soc. Exp. Biol. Med. 191:147-
152, 1989.
3. Combettes, L., Dumont, M., Berthon, B., Erlinger S., and Claret, M. Release of calcium from
the endoplasmic reticulum by bile acids in rat liver cells. J. Biol. Chem. 263:2299-2303, 1988.
4. Combettes, L., Berthon, B., Doucet, E., Erlinger, S., and Claret, M. Characteristics ofbile acid-
mediated Ca++ release from permeabilized liver cells and liver microsomes. J. Biol. Chem.
264:157-167, 1989.
5. Combettes, L., Berthon, B., Doucet, E., Erlinger, S., and Claret, M. Bile acids mobilise internal
Ca++ independently ofexternal Ca++ in rat hepatocytes. Eur. J. Biochem. 190:619-623, 1990.
6. Beuers, U., Thiel, M., Bardenheuer, H., andPaumgartner, G. Tauroursodeoxycholic acid inhibits
the cytosolic Ca++ increase in human neutrophils stimulated by formyl-methionyl-leucyl-
phenylalanine. Biochem. Biophys. Res. Commun. 171:1115-1121, 1990.
7. Beuers, U., Nathanson, M.H., and Boyer, J.L. Effects of tauroursodeoxycholic acid on cytoso-
lic Ca++ signals in isolated rat hepatocytes. Gastroenterol. 104:604-612, 1993.
8. Beuers, U., Nathanson, M.H., Isales, C.M., and Boyer, J.L. Tauroursodeoxycholic acid stimu-
lates hepatocellular exocytosis and mobilizes extracellular Ca++, mechanisms defective in
cholestasis. J. Clin. Invest. 92:2984-2993, 1993.
9. Beuers, U., Throckmorton, D.C., Anderson, M.S., Isales, C.M., Thasler, W., Kullak-Ublick,
G.A., Sauter, G., Koebe, H.G., Paumgartner, G., and Boyer, J.L. Tauroursodeoxycholic acid acti-
vates protein kinase C in isolated rat hepatocytes. Gastroenterol. 110:1553-1563, 1996.
10. Bouscarel, B., Fromm, H., and Nussbaum, R. Ursodeoxycholate mobilizes intracellular Ca++
and activates phosphorylase a in isolated hepatocytes. Am. J. Physiol. 264:G243-G251, 1993.
11. Bouscarel, B., Gettys, T.W., Fromm, H., and Dubner, H. Ursodeoxycholic acid inhibits
glucagon-induced cAMP formation in hamster hepatocytes: a role for PKC. Am. J. Physiol.
268:G300-G310, 1995.
12. Stravitz, R.T., Rao, Y.P., Vlahcevic, Z.R., Gurley, E.C., Jarvis, W.D., and Hylemon, P.B.
Hepatocellular protein kinase C activation by bile acids: implications for regulation of choles-
terol 7a-hydroxylase. Am. J. Physiol. 271:G293-G303, 1996.
13. Nathanson, M.H. and Schlosser, S.F. Calcium signaling mechanisms in liver in health and dis-
ease. Progr. Liver Dis. 12:1-27, 1997.
14. Exton, J.H. Role of phosphoinositides in the regulation of liver function. Hepatol. 8:152-166,
1988.
15. Kitani, K. Hepatoprotective effect of ursodeoxycholate in experimental animals. In:
Paumgartner, G., Stiehl, A., Barbara, L., andRoda, E., eds. Strategiesfor the treatment ofhepa-
tobiliary diseases. Lancaster., England: Kluwer Academic Publishers., 1990. pp. 43-56.
16. Heuman, D.M., Mills, A.S., McCall, J., Hylemon, P.B., Pandak, W.M., and Vlahcevic, Z.R.
Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused
by more hydrophobic bile salts: in vivo studies in the rat. Gastroenterol. 100:203-211, 1991.
17. Galle, P.R., Theilmann, L., Raedsch, R., Otto, G., and Stiehl, A. Ursodeoxycholate reduces
hepatotoxicity of bile salts in primary human hepatocytes. Hepatol. 12:486-491, 1990.346 Beuers: Bile acids andhepatocellular signaling and secretion
18. Burgoyne, R.D. and Morgan, A. Regulated exocytosis. Biochem. J. 293:305-316, 1993.
19. Benedetti, A., Strazzabosco, M., Ng, O.C., and Boyer, J.L. Regulation of activity and apical tar-
geting ofthe Cl-/HCO3- exchanger in rat hepatocytes. Proc. Natl. Acad. Sci. USA 91:792-796,
1994.
20. Boyer, J.L. and Soroka, C.J. Vesicle targeting to the apical domain regulates bile excretory func-
tion in isolated rat hepatocyte couplets. Gastroenterol. 109:1600-1611, 1995.
21. Larkin, J.M. and Palade, G.E. Transcytotic vesicular carriers for polymeric IgA receptors accu-
mulate in rat hepatocytes after total biliary obstruction. J. Cell Sci. 98:205-216, 1991.
22. Barr, V.A. and Hubbard, A.L. Newly synthesized hepatocyte membrane proteins are transport-
ed in transcytotic vesicles in the bile duct-ligated rat. Gastroenterol. 105:554-571, 1993.
23. Bruck, R., Nathanson, M.H., Roelofsen, H., and Boyer, J.L. Effects of protein kinase C and
cytosolic Call on exocytosis in the isolated perfused rat liver. Hepatol. 20:1032-1040, 1994.
24. Corasanti, J.G., Smith, N.D., Gordon, E.R., and Boyer, J.L. Proteinkinase C agonists inhibit bile
secretion independently of effects on the microcirculation in the isolated perfused rat liver.
Hepatol. 10:8-13, 1989.
25. Roelofsen, H., Ottenhoff, R., Oude Elferink, R.P.J., and Jansen, P.L.M. Hepatocellular organic-
anion transport is regulated by protein kinase C. Biochem. J. 278:637-641, 1991.
26. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein
kinase C. Science 258:607-614, 1992.
27. Hug, H. and Sarre, T.F. Protein kinase C isoenzymes: divergence in signal transduction?
Biochem. J. 291:329-343, 1993.
28. Nakamura, S. and Nishizuka, Y. Lipid mediators and protein kinase C activation for the intra-
cellular signaling network. J. Biochem. 115:1029-1034, 1994.
29. Exton, J.H. Signaling through phosphatidylcholine breakdown. J. Biol. Chem. 265:1-4, 1990.
30. Rao,Y.P., Hylemon, P.B., Vlahcevic, Z.R., and Stravitz, R.T. Activation of protein kinase C iso-
forms by bile acids in vitro [Abstract]. Hepatol. 24:31iA, 1996.
31. Poupon, R.E. and Poupon, R. Ursodeoxycholic acid therapy ofchronic cholestatic conditions in
adults and children. Pharmacol. Ther. 66:1-15, 1995.
32. Heathcote, E.J., Lindor, K.D., Poupon, R., et al. Combined analysis of French, American and
Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cir-
rhosis. Gastroenterol. 108:A1082, 1995.
33. Lindor, K.D., Themeau, T.M., Jorgensen, R.A., Malinchoc, M., and Dickson, E.R. Effects of
ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterol.
110:1515-1518, 1996.
34. Beuers, U., Spengler, U., Kruis, W., Aydemir, U., Wiebecke, B., Heldwein, W., Weinzierl, M.,
Pape, G.R., Sauerbruch, T., and Paumgartner G. Ursodeoxycholic acid for treatment ofprimary
sclerosing cholangitis: a placebo-controlled trial. Hepatol. 16:707-714, 1992.
35. Stiehl, A., Walker, S., Stiehl, S., Rudolph, G., Hofmann, W.J., and Theilmann, L. Effect of
ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year
pilot study with a placebo-controlled study period. J. Hepatol. 20:57-64, 1994.
36. Lindor, K.D. and the Mayo PSC/UDCA study group. A randomized trial of ursodeoxycholic
acid in the treatment ofprimary sclerosing cholangitis. Gastroenterology 110:A-844, 1996.
37. Colombo, C., Crosignani, A., Assaisso, M., Battezzati, P.M., Podda, M., Giunta, A., Zimmer-
Nechemias, L., and Setchell, K.D.R. Ursodeoxycholic acid therapy in cystic fibrosis-associated
liver disease: a dose-response study. Hepatol. 16:924-930, 1992.
38. Jacquemin, E., Hermans, D., Myara, A., Habes, D., Debray, D., Hadchouel, M., Sokal, E.M.,
and Bernard, 0. Ursodeoxycholic acid therapy in pediatric patients with progressive familial
intrahepatic cholestasis. Hepatol. 25:519-523, 1997.
39. Beuers, U., Kullak-Ublick ,G.A., and Paumgartner, G. Mechanisms of action of ursodeoxy-
cholic acid in cholestatic syndromes. In: Strazzabosco, M., Benedetti, A., and Alvaro, D., eds.
Vanishing bile duct syndromes. KluwerAcademic., Lancaster., UK., 1997. pp. 230-237.
40. Haussinger, D., Saha, N., Hallbrucker, C., Lang, F., and Gerok, W. Involvement of microtubules
in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver.
Biochem. J. 291:355-360, 1993.